Prostate Cancer News Archive
The later a man's testosterone level dropped below 12.1 nmol/L, the lower his lifetime risk for prostate cancer.
Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.
Use of intensity-modulated radiation therapy for prostate cancer increased from 3.5% to 64% from 2002 to 2012.
In a case-control study, men who had ever used non-steroid anti-inflammatory drugs had a 23% decreased risk of prostate cancer.
Use of active surveillance for very low-risk prostate cancer rose from 11.6% of patients in 2010 to 27.3% in 2013, study finds.
Following curative treatment for localized PCa, 5-year PCa-specific survival rates are higher for patients with initial lymph node or locoregional metastases versus initial metastases in bone only or in multiple sites.
Findings from this comparative study indicate a favorable failure-free survival and progression-free survival with Standard of Care plus abiraterone acetate and prednisone.
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
The researchers found that there was no difference between the 6- and 2-fraction groups in baseline and post-implantation IPSS scores.
A European trial found a survival benefit from PCa screening and a US trial did not, but a new analysis finds that both trials provide compatible evidence that screening decreases PCa mortality.
In a study, the risk for heart failure was 81% higher among patients who received androgen deprivation therapy.
Patients are more likely to receive intensity-modulated radiation therapy if they are managed by urology practices with an ownership interest in the modality, study finds.
The six-month cumulative incidence of myocardial infarction was 2.0% and 0.7% in patients with cancer and controls, respectively.
Prostate cancer patients accurately report their comorbidities, and participants in cancer clinical trials report more adverse events than trial investigators.
Improvement in BMD was seen with denosumab, which also reduced the incidence of new radiographic vertebral fractures in one high-quality trial.
Men with 1 high-risk factor experience better outcomes following treatment than those with 2 or 3 high-risk factors, study finds.
Study of men with intermediate- or high-risk prostate cancer finds facility-level racial disparity in use of definitive treatment.
A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.
63% of patients were managed initially with observation.
Nearly 1 in 3 patients diagnosed with Gleason 3+4 favorable intermediate-risk prostate cancer had their disease upgraded or upstaged at radical prostatectomy.
Most common infection in prostate biopsy was E. coli, followed by mild bleeding.
Throughout the study, a total of 115 lobes were treated and 82% achieved absent clinically significant cancer.
Researchers calculated that the absolute increase in lifetime risk of prostate cancer associated with vasectomy was just 0.6%.
Study reveals that a quarter of men with low-volume intermediate-risk prostate cancer had adverse pathologic features found at radical prostatectomy.
Every additional 4 inches of height was associated with a 21% increase in risk of being diagnosed with high-grade prostate cancer, and a 17% increased risk of dying from prostate cancer.
Randomized trial found no significant difference in all-cause and cancer-specific survival between radical prostatectomy and observation for localized prostate cancer.
Across time, only African-American race correlated with greater regret.
Men with prostate cancer and at least one additional primary cancer are enriched for harboring a germline deleterious mutation in a cancer-predisposing gene.
Over a 10-year period, radical prostatectomy use increased steadily while radiotherapy use declined
Both findings on biopsy also predict a lower odds of high-grade cancer.
Prostate cancer patients on active surveillance who have no cancer found on confirmatory biopsy have a reduced risk of grade and volume reclassification.
Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing
No added benefit was seen with the addition of biomarkers for African-American men.
New findings suggest that clinicians consider the pathologic characteristics of the primary tumor as well as the burden of LN metastases when deciding on management, investigators say.
Radiotherapy for prostate cancer patients with persistently elevated PSA after radical surgery improved survival only among those with worse pathologic characteristics.
High-income counties had far higher diagnosis rates for the four cancers than low-income counties, but the combined mortality rate was similar for both.
The researchers found that the median overall survival was 31.2 and 26.0 months in the PRO and usual care groups, respectively.
Some men who undergo multigene testing for inherited prostate cancer misinterpret findings of variants of uncertain significance.
Younger patients who chose surgery vs radiation for initial treatment had a 48% survival advantage.
Extended pelvic lymph node dissection versus limited dissection during radical prostatectomy does not improve biochemical recurrence rates.
CBP was associated with a reduction in sperm concentration, sperm vitality, sperm total and progressive motility.
New findings establish single-dose radiotherapy as the standard of care for metastatic spinal canal compression, at least for patients with a short life expectancy, researcher says.
ECOG status and baseline PSA and PSADT are significantly associated with overall survival.
Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.
The researchers found that predicted monthly costs remained relatively stable throughout the observation period among the controls.
Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.
The 3-year overall survival rate among prostate cancer patients starting long-term hormone therapy was 83% vs 76% for men receiving abiraterone plus ADT vs ADT alone.
Urinary incontinence and diminished sexual function were common after a median follow-up of nearly 15 years, study finds.
Overall complication rates were similar between primary and salvage RARP groups, but there were some notable differences in prognosis.
Systematic biopsies always should be performed in conjunction with targeted biopsy in men with suspected clinically significant PCa at mpMRI.
The new test, IsoPSA, measures all PSA isoforms in serum and more accurately discriminates high-grade cancer from benign disease.
Combining testing of urinary T2:ERG, PCA3 at thresholds that detected aggressive prostate cancer improved specificity from 18% to 39%.
The investigators found that the percentage of patients diagnosed with stage I cancer increased significantly from 2013 to 2014 after the ACA was implemented.
Only luminal B prostate cancers were significantly associated with postoperative response to ADT in a subset analysis in retrospective cohorts.
A majority of active surveillance patients under age 60 did not progress to definitive prostate cancer treatment.
Targeting PI-RADS 4 and 5 lesions for confirmatory biopsy improves detection of clinically significant cancer.
Median overall survival was 9.3 months longer for black versus white patients with metastatic castration-resistant prostate cancer.
Fusion biopsy has improved over the last decade and increasingly detects clinically significant prostate cancer, according to data trends from one institution.
Highest quartile of alkaline phosphatase velocity in men who experience biochemical recurrence after radical prostatectomy is associated with 2-fold higher risk.
Systematic biopsy parameters identified patients at higher risk of positive surgical margins.
The laser procedure was successful for 7 selected patients with enlarged prostates and LUTS harboring low-risk prostate cancer.
The new risk models improve upon PI-RADS version 1.0 and ERPSC risk calculators used for prostate biopsy decisions.
Nomogram based on a cohort of men with high-risk prostate cancer is more accurate than the CAPRA and MSKCC nomograms, researchers report.
Each 10 mg/dL increase in total cholesterol is associated with a significant 23% greater odds of high-grade prostate cancer.
Men who present with prostate cancer bone metastasis and no visceral metastases have a median survival time of 37 months, study finds.
But PSA density and body mass index are associated with prostate cancer reclassification.
Men who attended yoga classes had less fatigue and better sexual and urinary function than those in the comparison group.
Spike in PSA level after starting abiraterone does not affect progression-free or overall survival, study finds.
Also increased risk of progression to metastatic disease compared with the general population.
Survival curves showed that metformin use with docetaxel did not improve prostate cancer specific survival or overall survival.
The US Preventive Services Task Force now suggests decisions about PSA testing should be made on an individual basis for men aged 55 to 69.
Study identifies PSADT cut-points that can aid in risk stratification of men with non-metastatic castration-resistant prostate cancer.
Highest vs lowest quartile of vitamin D binding protein associated with 55% lower odds of prostate cancer.
A family history of prostate cancer was not a major determinant of disease progression during active surveillance, according to a systematic review.
Regular aspirin use linked to lower risk of cancer mortality, especially colorectal, breast, and prostate cancer.
Pathologic Gleason scores, positive surgical margin rates, and PSA doubling times differentiate earlier from later biochemical recurrence after radical surgery.
Among men under the age of 65, men who got 3 to 5 hours of sleep per night had a 55% greater risk of dying of prostate cancer than men who got 7 hours of sleep per night.
Patients with longer hospital stays and pre-discharge complications were at increased risk of readmission within 30 days of discharge.
In 2014, 33.9% of men reported that their health care providers failed to communicate the benefits and risks of PSA-based screening, an increase from 2012.
Population-based prostate cancer screening with MRI has a significantly better risk/benefit ratio.
Select intermediate- and high-risk patients had no greater risks of metastases, AS failure, or interventions over a median of 4 years.
Study finds no difference in metastasis-free survival observed after 15 years compared with radiation therapy or radical prostatectomy.
In a study, systematic biopsy detected clinically significant prostate cancer in only 3% of men with negative findings on multiparametic MRI.
Findings from 2 new studies could enable more informed patient counseling about choice of therapy.
Researchers found no evidence of worse cancer outcomes with nerve-sparing surgery.
A population-based study showed no association between total prostate cancer risk and testosterone replacement therapy (TRT).
At 6 months of treatment, bone imaging showed stable disease in 94% of patients with available data, study finds.
In multiparametric magnetic resonance imaging, rectal distension have a negative effect on T2-weighted and diffusion-weighted images.
Men with Gleason score 3 + 4 were 4.65 times more likely to have upgrading than men with an initial Gleason score of 3 + 3 at 3 years.
Clinical or radiologic progression is less likely with abiraterone plus prednisone than cabazitaxel following first-line docetaxel, study finds.
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.
In a retrospective study, patients lived the longest if they received docetaxel followed by cabazitaxel and then abiraterone or enzalutamide.
In a survey, 3 in 5 urologists in the United States indicated they perform MRI-US guided biopsy in current practice.
From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.
Study compared PCa patients who underwent surgery or radiation treatment with a matched group of non-cancer controls.
In a study, each 1-unit increment in body mass index was associated with a 16% lower mortality risk.
Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.
Cancer-specific mortality rates dropped from 72.8% in 1995 to 55.8% in 2011, according to a Danish study.
Researchers compared targeted prostate biopsy based on biparametric magnetic resonance imaging with standard 12-core systematic biopsy.
Cancer mortality decreased by 20.1% between 1980 and 2014, from 240.2 to 192.0 deaths per 100 000 population.
Renal and Urology News Articles
- Tamsulosin Improves Clearance of Large Distal Ureteral Stones
- Post-Parathyroidectomy Calcium Requirement Linked to Preop ALP
- Sucroferric Oxyhydroxide Efficacy Similar to That of Sevelamer
- Calciphylaxis in CKD Patients Linked to Hypercoagulable Conditions
- Kidney Cancer Bone Metastasis Predictors Id'd
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)